Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

Abhishek Maiti,Naveen Pemmaraju,Steven M Kornblau,Elias Jabbour,Stefan Faderl,Nitin Jain,Marina Konopleva,Tapan M Kadia,Hagop M Kantarjian,Hayley Balkin,William G Wierda,Prithviraj Bose,Farhad Ravandi,Jan A Burger,Alessandra Ferrajoli,Gautam Borthakur,Yesid Alvarado,Joseph D Khoury,Rebecca Garris,Hind Al Azzawi ,Mary Ann Kelly ,Guillermo Garcia‐Manero ,Susan O’brien ,Philip A Thompson

doi:10.1182/blood-2020-136873

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

Abhishek Maiti, Naveen Pemmaraju + Show 22 more

Open Access

https://doi.org/10.1182/blood-2020-136873

Copy DOI

Journal: Blood	Publication Date: Nov 5, 2020
Citations: 5

Affiliation: The University of Texas MD Anderson Cancer Center, Hackensack University Medical Center, University of California, Irvine Medical Center

#Research Funding #Advisory Committees + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Frontline HCVAD with Nelarabine and Peg-Asparaginase in T-Acute Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LBL): Updated Results of a Phase II Trial

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Blood

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.